Efficacy of pembrolizumab plus lenvatinib as first-line treatment for metastatic renal cell carcinoma with multiple brain metastases

被引：0

作者：

Matsumoto, Daisuke ^{[1
]}

Naiki, Taku ^{[1
,2
]}

Naiki-Ito, Aya ^{[3
]}

Aoki, Maria ^{[1
]}

Kato, Shinji ^{[4
]}

Morikawa, Toshiharu ^{[2
]}

Shimizu, Nobuhiko ^{[2
]}

Gonda, Masakazu ^{[2
]}

Umemoto, Yukihiro ^{[1
]}

Yasui, Takahiro ^{[2
]}

机构：

[1] Nagoya City Univ, West Med Ctr, Dept Urol, 1-1-1 Hirate Cho,Kita Ku, Nagoya 4628508, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Dept Nephrourol, Nagoya, Japan

[3] Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Nagoya, Japan

[4] Nagoya City Univ, Grad Sch Med Sci, Dept Radiol, Nagoya, Japan

来源：

IJU CASE REPORTS | 2025年 / 8卷 / 01期

关键词：

brain neoplasms; lenvatinib; pembrolizumab; radiosurgery; renal cell carcinoma; CABOZANTINIB; SUNITINIB;

D O I：

10.1002/iju5.12786

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Patients with metastatic renal cell carcinoma have a poor prognosis and its specific pathogenesis remains unelucidated. Case presentation: At 78 years of age, a Japanese male patient was diagnosed with metastatic renal cell carcinoma (cT3N2M1 stage) and multiple brain metastases that were responsive to stereotactic radiation therapy followed by systemic combination induction therapy of pembrolizumab plus lenvatinib. Adverse events, including grade 3 hypertension, grade 2 eruption, and elevated grade 2 fever, were controlled by a dose reduction or suspension of drugs. The patient eventually showed a tolerance for continuing with 8 mg lenvatinib. Fourteen months after the initiation of treatment, and on 8 mg lenvatinib, this patient showed no sign of disease progression at the last follow-up. Conclusion: We detail the absence of disease progression in a metastatic renal cell carcinoma case with multiple brain metastases more than 1 year after stereotactic radiation therapy followed by first-line pembrolizumab plus lenvatinib.

引用

页码：5 / 9

页数：5

共 13 条

[1] Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61) a single-arm, multicentre, phase 2 trial [J].

Albiges, Laurence ;

Gurney, Howard ;

Atduev, Vagif ;

Suarez, Cristina ;

Climent, Miguel A. ;

Pook, David ;

Tomczak, Piotr ;

Barthelemy, Philippe ;

Lee, Jae Lyun ;

Stus, Viktor ;

Ferguson, Thomas ;

Wiechno, Pawel ;

Gokmen, Erhan ;

Lacombe, Louis ;

Gedye, Craig ;

Perini, Rodolfo F. ;

Sharma, Manish ;

Peng, Xiang ;

Lee, Chung-Han .

LANCET ONCOLOGY, 2023, 24 (08) :881-891

[2] A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases [J].

Chevreau, Christine ;

Ravaud, Alain ;

Escudier, Bernard ;

Amela, Eric ;

Delva, Remy ;

Rolland, Frederic ;

Tosi, Diego ;

Oudard, Stephane ;

Blanc, Ellen ;

Ferlay, Celine ;

Negrier, Sylvie .

CLINICAL GENITOURINARY CANCER, 2014, 12 (01) :50-54

[3] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[4]

Derosa L., 2016, ANN ONCOL, V27, pvi266vi295

[5] Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study [J].

Flippot, Ronan ;

Dalban, Cecile ;

Laguerre, Brigitte ;

Borchiellini, Delphine ;

Gravis, Gwenaelle ;

Negrier, Sylvie ;

Chevreau, Christine ;

Joly, Florence ;

Geoffrois, Lionnel ;

Ladoire, Sylvain ;

Mahammedi, Hakim ;

Rolland, Frederic ;

Gross-Goupil, Marine ;

Deluche, Elise ;

Priou, Frank ;

Laramas, Mathieu ;

Barthelemy, Philippe ;

Narciso, Berengere ;

Houede, Nadine ;

Culine, Stephane ;

Oudard, Stephane ;

Chenot, Marina ;

Tantot, Florence ;

Chabaud, Sylvie ;

Escudier, Bernard ;

Albiges, Laurence .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (23) :2008-+

[6] Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma [J].

Hirsch, Laure ;

Chanza, Nieves Martinez ;

Farah, Subrina ;

Xie, Wanling ;

Flippot, Ronan ;

Braun, David A. ;

Rathi, Nityam ;

Thouvenin, Jonathan ;

Collier, Katharine A. ;

Seront, Emmanuel ;

de Velasco, Guillermo ;

Dzimitrowicz, Hannah ;

Beuselinck, Benoit ;

Xu, Wenxin ;

Bowman, I. Alex ;

Lam, Elaine T. ;

Abuqayas, Bashar ;

Bilen, Mehmet Asim ;

Varkaris, Andreas ;

Zakharia, Yousef ;

Harrison, Michael R. ;

Mortazavi, Amir ;

Barthelemy, Philippe ;

Agarwal, Neeraj ;

McKay, Rana R. ;

Brastianos, Priscilla K. ;

Krajewski, Katherine M. ;

Albiges, Laurence ;

Harshman, Lauren C. ;

Choueiri, Toni K. .

JAMA ONCOLOGY, 2021, 7 (12) :1815-1823

[7] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Tannir, N. M. ;

McDermott, D. F. ;

Frontera, O. Aren ;

Melichar, B. ;

Choueiri, T. K. ;

Plimack, Elizabeth R. ;

Barthelemy, P. ;

Porta, C. ;

George, S. ;

Powles, T. ;

Donskov, F. ;

Neiman, V. ;

Kollmannsberger, C. K. ;

Salman, P. ;

Gurney, H. ;

Hawkins, R. ;

Ravaud, A. ;

Grimm, M. -O. ;

Bracarda, S. ;

Barrios, C. H. ;

Tomita, Y. ;

Castellano, D. ;

Rini, B. I. ;

Chen, A. C. ;

Mekan, S. ;

McHenry, M. B. ;

Wind-Rotolo, M. ;

Doan, J. ;

Sharma, P. ;

Hammers, H. J. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) :1277-1290

[8] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma [J].

Motzer, Robert ;

Alekseev, Boris ;

Rha, Sun-Young ;

Porta, Camillo ;

Eto, Masatoshi ;

Powles, Thomas ;

Gruenwald, Viktor ;

Hutson, Thomas E. ;

Kopyltsov, Evgeny ;

Mendez-Vidal, Maria J. ;

Kozlov, Vadim ;

Alyasova, Anna ;

Hong, Sung-Hoo ;

Kapoor, Anil ;

Alonso Gordoa, Teresa ;

Merchan, Jaime R. ;

Winquist, Eric ;

Maroto, Pablo ;

Goh, Jeffrey C. ;

Kim, Miso ;

Gurney, Howard ;

Patel, Vijay ;

Peer, Avivit ;

Procopio, Giuseppe ;

Takagi, Toshio ;

Melichar, Bohuslav ;

Rolland, Frederic ;

De Giorgi, Ugo ;

Wong, Shirley ;

Bedke, Jens ;

Schmidinger, Manuela ;

Dutcus, Corina E. ;

Smith, Alan D. ;

Dutta, Lea ;

Mody, Kalgi ;

Perini, Rodolfo F. ;

Xing, Dongyuan ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14) :1289-1300

[9] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Motzer, Robert J. ;

Penkov, Konstantin ;

Haanen, John ;

Rini, Brian ;

Albiges, Laurence ;

Campbell, Matthew T. ;

Venugopal, Balaji ;

Kollmannsberger, Christian ;

Negrier, Sylvie ;

Uemura, Motohide ;

Lee, Jae L. ;

Vasiliev, Aleksandr ;

Miller, Wilson H., Jr. ;

Gurney, Howard ;

Schmidinger, Manuela ;

Larkin, James ;

Atkins, Michael B. ;

Bedke, Jens ;

Alekseev, Boris ;

Wang, Jing ;

Mariani, Mariangela ;

Robbins, Paul B. ;

Chudnovsky, Aleksander ;

Fowst, Camilla ;

Hariharan, Subramanian ;

Huang, Bo ;

di Pietro, Alessandra ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) :1103-1115

[10] Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma [J].

Nakagawa, Takashi ;

Kijima, Toshiki ;

Imasato, Naoki ;

Nagoshi, Akihiko ;

Nakamura, Gaku ;

Uematsu, Toshitaka ;

Suzuki, Issei ;

Nishihara, Daisaku ;

Kamai, Takao .

IJU CASE REPORTS, 2022, 5 (04) :293-296

← 1 2 →